Selank SK
Tuftsin analogue
Synthetic heptapeptide analogue of tuftsin, studied for effects on cytokine expression, monoamine metabolism and hippocampal BDNF expression in rats.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- Tuftsin analogue
- Category
- Neuro, Cognitive & Sleep
- Type
- Single compound
- Abbreviation
- SK
- Development and regulatory status
- Not FDA-approved; reported Russian clinical use, regional status unconfirmed
What researchers study
Synthetic heptapeptide analogue of tuftsin, an immune-derived peptide. Reported to modulate cytokine expression, monoamine metabolism and enkephalin-degrading enzymes, and to raise hippocampal BDNF expression in rats.
Research areas
- Anxiety-related behaviour in rodent models
- Cytokine and immune-signalling studies
- Enkephalin-degrading enzyme inhibition assays
- Monoamine and BDNF expression in rat brain
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- human trial
A Russian study of 62 patients with generalized anxiety disorder and neurasthenia compared selank with medazepam and reported similar anxiolytic effects on psychometric scales
- cell culture
In vitro, selank suppressed IL-6 gene expression in blood cells from patients with depression but not healthy controls
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- SemaxRelated Russian heptapeptide acting mainly through neurotrophin expression and melanocortin pathways
- Semax + SelankBlend of both peptides for combined cognitive and anxiety-pathway studies
